Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/16/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- U.S. Commerce Department to sell up to 9.9M GlobalFoundries shares
- AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Wall Street ends lower as oil spikes and the benchmark Treasury yield breaches 5%
Biogen (BIIB) PT Raised to $305 at Canaccord Genuity
October 23, 2019 5:14 AM EDTCanaccord Genuity analyst Sumant Kulkarni raised the price target on Biogen (NASDAQ: BIIB) to $305.00 (from $285.00) while maintaining a Hold rating.
... MoreBiogen (BIIB) PT Raised to $297 at BMO Capital
October 23, 2019 4:44 AM EDTBMO Capital analyst George Farmer raised the price target on Biogen (NASDAQ: BIIB) to $297.00 (from $250.00) while maintaining a Market Perform rating.
The analyst comments "After a failed futility analysis reported last March, new results from the Phase 3 trials, EMERGE and ENGAGE, now support... More
Biogen (BIIB) PT Raised to $310 at Jefferies
October 22, 2019 1:45 PM EDTJefferies analyst Michael Yee raised the price target on Biogen (NASDAQ: BIIB) to $310.00 (from $255.00) while maintaining a Hold rating.
stock pricing in renewed hopes againasks if M&A could be next... MoreBiogen (BIIB) News 'Somewhat Astonishing', Shares Could Trade Back Toward Low-$300s - RBC
October 22, 2019 7:32 AM EDTRBC Capital analyst Brian Abrahams weighed in on news Biogen (NASDAQ: BIIB) will pursue regulatory approval of aducanumab in Alzheimer's.
"We expect more clarity on BIIB's earnings call this morning but believe that given the multi-$B potential opportunity, we could see shares initially... More
Biogen (BIIB) Surges 18.5% Pre-Market After Announcing Plans to Pursue Regulatory Approval for Aducanumab in Alzheimer’s Disease
October 22, 2019 6:41 AM EDTBiogen (NASDAQ: BIIB) Surges 18.5% Pre-Market After Announcing Plans to Pursue Regulatory Approval for Aducanumab in Alzheimers Disease
... More